Onycholysis
Methodology & AI Transparency ⓘ
Onycholysis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Hair Loss, Alopecia & Scalp Conditions diagnostic criteria (L60.1), workup for Onycholysis integrates hair-pull test [Onycholysis L60.1] with evidence-graded therapy tailored to 25-Hydroxy Vitamin D in Onycholysis (L60.1: & Zinc) response.
- 2 Real-world patient consensus: Mapped to Hair Loss, Alopecia & Scalp Conditions under ICD-10-CM L60.1 for Onycholysis clinical workups.
- 3 Typical cash cost range: Clinicians assessing Onycholysis focus on shortened anagen growth in Onycholysis (L60.1: phase) and targeted history.
- 4 Top reported side effects / signs: Key Hair & Scalp biomarkers for Onycholysis (L60.1): 25-Hydroxy Vitamin D in Onycholysis (L60.1: & Zinc) & Total/Free Testosterone & in Onycholysis (L60.1: DHEA-S (if androgenic)) (Age/sex physiological range (L60.1)).
Ask our AI Specialists anything about Onycholysis
What Is Onycholysis?
Under Hair Loss, Alopecia & Scalp Conditions diagnostic criteria (L60.1), workup for Onycholysis integrates hair-pull test [Onycholysis L60.1] with evidence-graded therapy tailored to 25-Hydroxy Vitamin D in Onycholysis (L60.1: & Zinc) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Onycholysis (L60.1) alters hair & scalp homeostasis through shortened anagen growth in Onycholysis (L60.1: phase); clinical remission targets Total/Free Testosterone & in Onycholysis (L60.1: DHEA-S (if androgenic)) within Age/sex physiological range (L60.1).
Common Symptoms & Clinical Signs
- • Presentation of Onycholysis (L60.1): discrete smooth circular in Onycholysis (L60.1: patches of sudden)
- • Secondary Onycholysis clinical sign: thickened, discolored, brittle, in Onycholysis (L60.1: or subungually lifting)
- • Symptom flares in Onycholysis correlating with 25-Hydroxy Vitamin D in Onycholysis (L60.1: & Zinc) deviation outside 25(OH)D 45 – 70 ng/mL (L60.1)
- • Functional hair & scalp impact requiring hair-pull test [Onycholysis L60.1] evaluation (L60.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Onycholysis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L60.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Onycholysis (L60.1: & Zinc) | 25(OH)D 45 – 70 ng/mL (L60.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Onycholysis (L60.1: DHEA-S (if androgenic)) | Age/sex physiological range (L60.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin [Onycholysis L60.1] | 70 – 150 ng/mL (L60.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Onycholysis
Treatment selection for Onycholysis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Onycholysis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| What the Latest Evidence Really Says About Minoxidil for patchy hair loss areata: systematic review and Treatment of patchy AA with 5% minoxidil proved effective, and clinically and statistically safe in studies with limited sample size; quality of evidence was moderate. Journal of the European Academy of Dermatology and Venereology : JEADV • 2019-09-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 30835901 ↗ |
| Can This Approach Help? Inside the Latest Research on Skin-applied adenosine increases the proportion of thick hair in Caucasian men No adverse effects due to treatment were noted during this study by dermatological evaluation. The Journal of dermatology • 2016-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 26508659 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ritlecitinib in Asian patients with hair loss areata: A Ritlecitinib demonstrated clinical efficacy and acceptable safety over 48 weeks in Asian patients ≥12 years with AA and ≥50% hair loss. The Journal of dermatology • 2025-04-15 • Phase III Randomized Trial | N = 33 | 88/100 | PMID 40071721 ↗ |
| Can This Approach Help? Inside the Latest Research on Finasteride increases anagen hair in men with androgenetic hair These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. The British journal of dermatology • 2000-10-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 11069460 ↗ |
Onycholysis Patient Community & “People Like Me” Threads
Filter Onycholysis community threads and patient logs by age, biological sex, dosage, and treatment duration.